188 related articles for article (PubMed ID: 18240153)
1. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease.
Martin WR; Wieler M; Stoessl AJ; Schulzer M
Ann Neurol; 2008 Mar; 63(3):388-94. PubMed ID: 18240153
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
Bohnen NI; Albin RL; Koeppe RA; Wernette KA; Kilbourn MR; Minoshima S; Frey KA
J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
4. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Lee CS; Samii A; Sossi V; Ruth TJ; Schulzer M; Holden JE; Wudel J; Pal PK; de la Fuente-Fernandez R; Calne DB; Stoessl AJ
Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of
Sanchez-Catasus CA; Bohnen NI; Yeh FC; D'Cruz N; Kanel P; Müller MLTM
J Nucl Med; 2021 Apr; 62(4):545-552. PubMed ID: 32859707
[TBL] [Abstract][Full Text] [Related]
6. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.
Bohnen NI; Müller ML; Zarzhevsky N; Koeppe RA; Bogan CW; Kilbourn MR; Frey KA; Albin RL
Brain; 2011 Aug; 134(Pt 8):2358-65. PubMed ID: 21653540
[TBL] [Abstract][Full Text] [Related]
7. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
8. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease.
de la Fuente-Fernández R; Schulzer M; Kuramoto L; Cragg J; Ramachandiran N; Au WL; Mak E; McKenzie J; McCormick S; Sossi V; Ruth TJ; Lee CS; Calne DB; Stoessl AJ
Ann Neurol; 2011 May; 69(5):803-10. PubMed ID: 21246604
[TBL] [Abstract][Full Text] [Related]
9. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
10. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.
Butcher NJ; Marras C; Pondal M; Rusjan P; Boot E; Christopher L; Repetto GM; Fritsch R; Chow EWC; Masellis M; Strafella AP; Lang AE; Bassett AS
Brain; 2017 May; 140(5):1371-1383. PubMed ID: 28369257
[TBL] [Abstract][Full Text] [Related]
13. PET imaging with [
Tang J; Xu Y; Liu C; Fang Y; Cao S; Zhao C; Huang H; Zou M; Chen Z
Nucl Med Biol; 2020; 90-91():1-9. PubMed ID: 32861175
[TBL] [Abstract][Full Text] [Related]
14. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
15. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
[TBL] [Abstract][Full Text] [Related]
16. Multimodal dopaminergic and free-water imaging in Parkinson's disease.
Yang J; Archer DB; Burciu RG; Müller MLTM; Roy A; Ofori E; Bohnen NI; Albin RL; Vaillancourt DE
Parkinsonism Relat Disord; 2019 May; 62():10-15. PubMed ID: 30639168
[TBL] [Abstract][Full Text] [Related]
17. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand.
Li X; Chen Z; Tang J; Liu C; Zou P; Huang H; Tan C; Yu H
Arch Pharm (Weinheim); 2014 May; 347(5):313-9. PubMed ID: 24497196
[TBL] [Abstract][Full Text] [Related]
19. Quantitative study of
Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
[TBL] [Abstract][Full Text] [Related]
20. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]